Last €14.63 EUR
Change Today -0.69 / -4.52%
Volume 54.7K
FYB On Other Exchanges
Symbol
Exchange
Xetra
As of 3:35 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

formycon ag (FYB) Snapshot

Open
€15.48
Previous Close
€15.32
Day High
€16.03
Day Low
€14.35
52 Week High
01/30/15 - €16.03
52 Week Low
05/2/14 - €6.20
Market Cap
126.2M
Average Volume 10 Days
30.6K
EPS TTM
€-0.90
Shares Outstanding
8.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FORMYCON AG (FYB)

Related News

No related news articles were found.

formycon ag (FYB) Related Businessweek News

No Related Businessweek News Found

formycon ag (FYB) Details

Formycon AG, a biopharmaceutical company, develops and markets biosimilar products. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is based in Planegg, Germany.

Founded in 1999

formycon ag (FYB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

formycon ag (FYB) Key Developments

Formycon AG Reports Earnings Results for the First Half of 2014; Provides EBITDA Outlook for the full year 2014

Formycon AG reported earnings results for the first half of 2014. In the first half of 2014, the company recorded a turnover of €7.4 million against €0.2 million reported last year. This increase is substantially due to the high revenues achieved as a result of the above mentioned licence agreement and the resulting development alliance. The company's EBITDA amounted to €2.6 million in the first half of 2014 against negative €3.5 million reported last year. Overall, the company expects to achieve positive EBITDA for the business year 2014.

Formycon AG Presents at German Equity Forum 2014, Nov-26-2014 09:30 AM

Formycon AG Presents at German Equity Forum 2014, Nov-26-2014 09:30 AM. Venue: Frankfurt, Germany. Speakers: Carsten Brockmeyer, Chief Executive Officer and Member of Executive Board, Nicolas Combé, Co-Founder, Chief Financial Officer and Member of Executive Board.

Formycon AG Commences Development of its Third Product

Formycon announced that the development of its third product has now commenced, which like its first two products aims to replicate an established biopharmaceutical drug. These products will be part of the so-called 'third wave' of biosimilars, referring to the major, multi-billion-dollar blockbuster drugs created through biotechnology for indications in the areas of ophthalmology, autoimmune disease, and metabolic and blood clotting disorders for which patent protection will expire beginning in 2020. Formycon AG has already licensed out the first of the third-wave biosimilar candidates which it has developed to Santo Holding GmbH (Bioeq GmbH) and is currently in discussions for the out-licensing of further product candidates.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FYB:GR €14.63 EUR -0.69

FYB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FYB.
View Industry Companies
 

Industry Analysis

FYB

Industry Average

Valuation FYB Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FORMYCON AG, please visit www.formycon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.